Peraso (PRSO) 10-Q 13 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 01, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	MoSys, Inc.
Entity Central Index Key	0000890394
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	MOSY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	CA
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		2,177,552
Entity File Number	000-32929
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0291941
Entity Address, Address Line One	2309 Bering Drive
Entity Address, City or Town	San Jose
Entity Address, Postal Zip Code	95131
City Area Code	408
Local Phone Number	418-7500
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 6,170	$ 7,104
Short-term investments	650
Accounts receivable	893	1,622
Inventories	1,215	1,148
Prepaid expenses and other	596	923
Total current assets	9,524	10,797
Property and equipment, net	193	279
Goodwill	0	420
Right-of-use lease asset	203
Other	139	260
Total assets	10,059	11,756
Current liabilities
Accounts payable	131	236
Deferred revenue	146	273
Short-term lease liability	197
Accrued expenses and other	1,249	1,402
Total current liabilities	1,723	1,911
Long-term liabilities	19	17
Convertible notes payable	2,858	2,671
Total liabilities	4,600	4,599
Commitments and contingencies (Note 4)
Stockholders’ equity
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 120,000 shares authorized; 2,178 shares and 2,148 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	2	2
Additional paid-in capital	243,217	243,022
Accumulated other comprehensive income	1
Accumulated deficit	(237,761)	(235,867)
Total stockholders’ equity	5,459	7,157
Total liabilities and stockholders’ equity	$ 10,059	$ 11,756

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	2,178,000	2,148,000
Common stock, shares outstanding	2,178,000	2,148,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net revenue
Total net revenue	$ 1,206	$ 4,343	$ 7,792	$ 13,149
Cost of net revenue	407	1,948	2,989	5,382
Gross profit	799	2,395	4,803	7,767
Operating expenses
Research and development	1,097	1,023	3,231	3,064
Selling, general and administrative	1,059	919	2,963	3,158
Impairment of goodwill	420	3,159	420	3,159
Total operating expenses	2,576	5,101	6,614	9,381
Loss from operations	(1,777)	(2,706)	(1,811)	(1,614)
Interest expense	(54)	(104)	(164)	(531)
Other income, net	30		81
Loss before income tax provision	(1,801)	(2,810)	(1,894)	(2,145)
Income tax provision		2		4
Net loss	(1,801)	(2,812)	(1,894)	(2,149)
Other comprehensive income, net of tax:
Net unrealized gains on available-for-sale securities			1
Comprehensive loss	$ (1,801)	$ (2,812)	$ (1,893)	$ (2,149)
Net loss per share
Basic and diluted	$ (0.83)	$ (6.83)	$ (0.88)	$ (5.25)
Shares used in computing net loss per share
Basic and diluted	2,171	412	2,161	409
Product [Member]
Net revenue
Total net revenue	$ 1,037	$ 4,056	$ 7,233	$ 11,811
Royalty and Other [Member]
Net revenue
Total net revenue	$ 169	$ 287	$ 559	$ 1,338

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning Balance at Dec. 31, 2017	$ 7,346		$ 232,034		$ (224,688)
Beginning Balance, shares at Dec. 31, 2017		404
Cumulative effect of accounting change	230				230
Issuance costs for the sale of common stock	(12)		(12)
Issuance of common stock for release of awards	(38)		(38)
Issuance of common stock for release of awards, shares		5
Stock-based compensation	93		93
Net income (loss)	348				348
Ending Balance at Mar. 31, 2018	7,967		232,077		(224,110)
Ending Balance, shares at Mar. 31, 2018		409
Beginning Balance at Dec. 31, 2017	7,346		232,034		(224,688)
Beginning Balance, shares at Dec. 31, 2017		404
Net income (loss)	(2,149)
Ending Balance at Sep. 30, 2018	5,815		232,422		(226,607)
Ending Balance, shares at Sep. 30, 2018		414
Beginning Balance at Mar. 31, 2018	7,967		232,077		(224,110)
Beginning Balance, shares at Mar. 31, 2018		409
Stock-based compensation	159		159
Net income (loss)	315				315
Ending Balance at Jun. 30, 2018	8,441		232,236		(223,795)
Ending Balance, shares at Jun. 30, 2018		409
Issuance of common stock for release of awards	(8)		(8)
Issuance of common stock for release of awards, shares		5
Stock-based compensation	194		194
Net income (loss)	(2,812)				(2,812)
Ending Balance at Sep. 30, 2018	5,815		232,422		(226,607)
Ending Balance, shares at Sep. 30, 2018		414
Beginning Balance at Dec. 31, 2018	$ 7,157	$ 2	243,022		(235,867)
Beginning Balance, shares at Dec. 31, 2018	2,148	2,148
Issuance of common stock for release of awards	$ (1)		(1)
Issuance of common stock for release of awards, shares		9
Stock-based compensation	(4)		(4)
Net income (loss)	10				10
Ending Balance at Mar. 31, 2019	7,162	$ 2	243,017		(235,857)
Ending Balance, shares at Mar. 31, 2019		2,157
Beginning Balance at Dec. 31, 2018	$ 7,157	$ 2	243,022		(235,867)
Beginning Balance, shares at Dec. 31, 2018	2,148	2,148
Unrealized gain on available-for-sale investments	$ 1
Net income (loss)	(1,894)
Ending Balance at Sep. 30, 2019	$ 5,459	$ 2	243,217	$ 1	(237,761)
Ending Balance, shares at Sep. 30, 2019	2,178	2,178
Beginning Balance at Mar. 31, 2019	$ 7,162	$ 2	243,017		(235,857)
Beginning Balance, shares at Mar. 31, 2019		2,157
Issuance of common stock for release of awards, shares		5
Stock-based compensation	119		119
Unrealized gain on available-for-sale investments	1			1
Net income (loss)	(103)				(103)
Ending Balance at Jun. 30, 2019	7,179	$ 2	243,136	1	(235,960)
Ending Balance, shares at Jun. 30, 2019		2,162
Issuance of common stock for release of awards	(3)		(3)
Issuance of common stock for release of awards, shares		16
Stock-based compensation	84		84
Net income (loss)	(1,801)				(1,801)
Ending Balance at Sep. 30, 2019	$ 5,459	$ 2	$ 243,217	$ 1	$ (237,761)
Ending Balance, shares at Sep. 30, 2019	2,178	2,178

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (1,894)	$ (2,149)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	148	486
Stock-based compensation	199	446
Amortization of intangible assets		83
Impairment of goodwill	420	3,159
Amortization of debt issuance costs		30
Accrued interest	164	500
Other	(11)
Changes in assets and liabilities
Accounts receivable	729	(822)
Inventories	(67)	395
Prepaid expenses and other assets	448	782
Accounts payable	(105)	(30)
Deferred revenue and other liabilities	(257)	(2,469)
Net cash provided by (used in) operating activities	(226)	411
Cash flows from investing activities:
Purchases of property and equipment	(62)	(45)
Proceeds from maturities of short-term investments	925
Purchases of short-term investments	(1,567)
Net cash used in investing activities	(704)	(45)
Cash flows from financing activities:
Issuance costs for sale of common stock		(12)
Taxes paid to net share settle equity awards	(4)	(46)
Net cash used in financing activities	(4)	(58)
Net increase (decrease) in cash and cash equivalents	(934)	308
Cash and cash equivalents at beginning of period	7,104	3,868
Cash and cash equivalents at end of period	6,170	4,176
Supplemental disclosure:
Issuance of convertible notes in settlement of accrued interest	$ 187	$ 846

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	Note 1. The Company and Summary of Significant Accounting Policies MoSys, Inc. (the Company) was incorporated in California in September 1991 and reincorporated in September 2000 in Delaware. The Company’s strategy and primary business objective is to be an IP-rich fabless semiconductor company focused on the development and sale of integrated circuit (IC) and related firmware products. Its Bandwidth Engine ICs combine the Company’s proprietary high-density embedded memory with its high-speed 10 gigabits per second and higher interface technology. The accompanying condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 or for any other future period. Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year. Reverse Stock Split On August 27, 2019, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by the Company’s stockholders and board of directors, respectively. As a result of the reverse stock split, which was effective August 28, 2019, every 20 shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split; stockholders who would otherwise hold a fractional share of the Company’s common stock received cash in an amount equal to the product obtained by multiplying (i) the closing sale price of the common stock on the effective date of the reverse stock split as reported on The Nasdaq Stock Market, by (ii) the number of shares of the common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest. All stock options and restricted stock units outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by 20 and, as applicable, multiplying the exercise price by 20, as a result of the reverse stock split. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Cash Equivalents and Investments The Company invests its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method. Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. There was no allowance for doubtful accounts receivable at either September 30, 2019 or December 31, 2018. Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded no material inventory write-downs during the three and nine months ended September 30, 2019 and $0.1 million of inventory write-downs during the three and nine months ended September 30, 2018. Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company's contracts have a single performance obligation to transfer products. Accordingly, the recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company its and generally under agreements with payment terms typically less than 60 days. The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. During the nine months ended September 30, 2019, the Company recognized revenue of $0.3 million that had been included in deferred revenue at December 31, 2018. See Note 5 for disaggregation of revenue by geography. Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products. Goodwill The Company determines the amount of potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired. If the carrying value of the reporting unit’s goodwill exceeds its fair value, then the Company must record an impairment charge equal to the difference. The Company performed its annual test for goodwill impairment as of September 1, 2019, and, due to a decrease in the price per share of its common stock, the test results indicated the goodwill carrying value was greater than its implied fair value. Further, the Company concluded a triggering event had occurred due to the sustained decrease in the price per share of its common stock and related reduced market capitalization as of September 30, 2019 and performed an additional test for impairment of its goodwill asset resulting in further indication that the goodwill carrying value was still greater than its implied fair value. As a result of both of these tests, the Company recorded non-cash impairment charges totaling $0.4 million. As a result of these charges, the Company’s goodwill balance was reduced to zero at September 30, 2019. Warrants As of September 30, 2019 and December 31, 2018, the Company had the following outstanding warrants to purchase common stock: Warrant type Number of shares Exercise Price Expiration date Pre-funded common stock 115,538 $ 0.02 None Common stock 33,125 $ 47.00 January 2023 Common stock 1,845,540 $ 6.00 October 2023 Per Share Amounts Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with the outstanding convertible notes. The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except per share amounts): Three months ended Nine months ended September 30, September 30, 2019 2018 2019 2018 Numerator: Net loss $ (1,801 ) $ (2,812 ) $ (1,894 ) $ (2,149 ) Denominator: Weighted-average common shares outstanding 2,171 412 2,161 409 Total shares: basic and diluted 2,171 412 2,161 409 Net loss per share: Basic and diluted $ (0.83 ) $ (6.83 ) $ (0.88 ) $ (5.25 ) The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): September 30, 2019 2018 Options to purchase common stock 81 17 Unvested restricted common stock units 91 19 Convertible debt 245 118 Warrants 1,994 33 Total 2,411 187 Recently Adopted Accounting Standards In 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) Codification Improvements to Topic 842 Leases (Topic 842): Targeted Improvements Leases (Topic 842): Codification Improvements, In 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718), Improvements to Employee Share-based Payment Accounting

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 2: Fair Value of Financial Instruments The estimated fair values of financial instruments outstanding were (in thousands): September 30, 2019 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,170 $ — $ — $ 6,170 Short-term investments 649 1 — 650 $ 6,819 $ 1 $ — $ 6,820 December 31, 2018 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 7,104 $ — $ — $ 7,104 The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): September 30, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 4,202 $ 4,202 $ — $ — Corporate notes and commercial paper $ 650 $ — $ 650 $ — December 31, 2018 Fair Value Level 1 Level 2 Level 3 Money market funds $ 632 $ 632 $ — $ — There were no transfers in or out of Level 1 and Level 2 securities during the three or nine months ended September 30, 2019.

Balance Sheet Detail

Balance Sheet Detail	9 Months Ended
	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Detail	Note 3. Balance Sheet Detail September 30, December 31, 2019 2018 (in thousands) Inventories: Work-in-process $ 755 $ 548 Finished goods 460 600 $ 1,215 $ 1,148

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4. Commitments and Contingencies Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the three or nine months ended September 30, 2019 or 2018 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements. Legal Matters The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts. .

Business Segments, Concentratio

Business Segments, Concentration of Credit Risk and Significant Customers	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Business Segments, Concentration of Credit Risk and Significant Customers	Note 5. Business Segments, Concentration of Credit Risk and Significant Customers The Company operates in one business segment and uses one measurement of profitability for its business. Net revenue is attributed to the United States and to all foreign countries based on the geographical location of the customer. The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 930 $ 3,652 $ 6,004 $ 10,393 Japan 179 364 1,431 2,206 Taiwan 97 155 225 311 Rest of world — 172 132 239 Total net revenue $ 1,206 $ 4,343 $ 7,792 $ 13,149 Customers who accounted for at least 10% of total net revenue were: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Customer A 33% 37% 27% 34% Customer B 19% 29% 20% 15% Customer C 19% *% *% *% Customer D 15% *% 18% 17% Customer E *% *% 17% 18% * Represents less than 10% Three customers accounted for 76% of accounts receivable at September 30, 2019. Three customers accounted for 63% of accounts receivable at December 31, 2018.

Income Tax Provision

Income Tax Provision	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax Provision	Note 6. Income Tax Provision The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2013 to 2018 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2009 to 2018. As of September 30, 2019, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 7. Stock-Based Compensation The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of September 30, 2019, was $0.2 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 2.2 years. The expense related to restricted stock units (RSUs) is recognized over a three-to-five year vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, as of September 30, 2019, was $0.3 million related to RSUs and is expected to be recognized as expense over a weighted-average period of approximately 2.3 years. For the three and nine months ended September 30, 2019 and 2018, there were no excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions. Valuation Assumptions The fair value of the Company’s stock options granted during the nine months ended September 30, 2019 and 2018 was estimated on the grant dates using the Black-Scholes valuation option-pricing model with the following assumptions: Nine Months Ended September 30, 2019 2018 Risk-free interest rate 2.5 % 2.2 % Volatility 128.4 % 109.5 % Expected life (years) 3.0 - 5.0 4.0 Dividend yield — % — % There were no awards granted during the three months ended September 30, 2019 and 2018. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. The expected volatility was based on the historical volatility of the Company’s stock price over the expected term of the options. The expected term of options granted was derived from historical data based on employee exercises and post‑vesting employment termination behavior. A dividend yield of zero is applied because the Company has never paid dividends, and has no intention to pay dividends in the near future. Prior to January 1, 2019, the stock‑based compensation expense recorded was adjusted based on estimated forfeiture rates. An annualized forfeiture rate has been used as a best estimate of future forfeitures based on the Company’s historical forfeiture experience. Stock‑based compensation expense was then adjusted in later periods if the actual forfeiture rate is different from the estimate. Upon the adoption of ASU No. 2016-09 on January 1, 2019, the Company changed its accounting policy and began accounting for forfeitures as they occur. Historically, estimated forfeitures were immaterial to the condensed consolidated financial statements. Common Stock Options and Restricted Stock A summary of option and RSU activity under the Company’s Amended and Restated 2010 Equity Incentive Plan (the 2010 Plan) is presented below (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2019 200 17 $ 83.80 Additional shares authorized under the Plan 2 — — RSUs granted (101 ) — — RSUs cancelled and returned to the Plan 1 — — Options granted (65 ) 65 $ 4.00 Balance as of March 31, 2019 37 82 $ 20.40 RSUs granted (6 ) — — Options cancelled and returned to the Plan 1 (1 ) $ 144.00 Balance as of June 30, 2019 32 81 $ 20.00 Plan termination (32 ) — $ — Balance as of September 30, 2019 - 81 $ 20.00 A summary of RSU activity under the Plan is presented below (in thousands, except for fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2019 14 $ 24.60 Granted 101 $ 4.00 Vested (8 ) $ 29.60 Cancelled (1 ) $ 25.20 Non-vested shares as of March 31, 2019 106 $ 4.60 Granted 6 $ 4.60 Vested (5 ) $ 16.20 Non-vested shares as of June 30, 2019 107 $ 4.00 Vested (16 ) $ 4.00 Non-vested shares as of September 30, 2019 91 $ 4.00 The total intrinsic value of the RSUs outstanding as of September 30, 2019 was $0.2 million. In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and, as a result, the 2010 Plan was automatically terminated. No future grants of awards will be made under the 2010 Plan, although it will continue to govern prior awards granted thereunder, until all such awards granted have been exercised, forfeited, canceled, expired or otherwise terminated in accordance with the terms of such grants. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares have been reserved for issuance. The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company. As of September 30, 2019, no awards had been granted under the 2019 Plan. The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2019 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $3.72 - $14.99 64 9.35 $ 3.96 11 $ 4.00 $ — $15.00 - $25.59 8 4.05 $ 15.00 5 $ 15.00 $ — $25.60 - $143.99 3 4.83 $ 41.88 2 $ 46.93 $ — $144.00 - $409.99 5 6.90 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 5.44 $ 430.64 1 $ 430.64 $ — $3.72 - $924.00 81 8.46 $ 20.36 24 $ 56.81 $ — There were no stock options exercised during the nine months ended September 30, 2019 or 2018.

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes	Note 8. Convertible Notes In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the “Purchase Agreement”) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the “Notes”), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $170.00 of Note principal per share of common stock to $11.434 of Note principal per share of common stock. The conversion price is subject to adjustment upon certain events, such as stock splits, reverse stock splits, stock dividends and similar kinds of transactions, as set forth in the Purchase Agreement. Pursuant to a security agreement, the Notes are secured by a security interest in all of the assets of the Company. Accrued interest is payable semi-annually in cash or in kind through the issuance of identical new Notes, or with a combination of the two, at the Company’s option. The Notes are noncallable and nonredeemable by the Company. The Notes are redeemable at the election of the holders if the Company experiences a fundamental change (as defined in the Notes), which generally would occur in the event (i) any person acquires beneficial ownership of shares of common stock of the Company entitling such person to exercise at least 40% of the total voting power of all of the shares of capital stock of the Company entitled to vote generally in elections of directors, (ii) an acquisition of the Company by another person through a merger or consolidation, or the sale, transfer or lease of all or substantially all of the Company’s assets, or (iii) the Company’s current directors cease to constitute a majority of the board of directors of the Company within a 12-month period, disregarding for this purpose any director who voluntarily resigns as a director or dies while serving as a director. Effective February 2018, pursuant to one amendment to the Notes, the redemption price was reduced from 120% to 100% of the principal amount of the Note to be repurchased plus accrued and unpaid interest as of the redemption date. No Note holder shall be entitled to convert such holder’s Note if effective upon the applicable conversion date (i) the holder would have beneficial ownership of more than 19.9% of the voting capital stock of the Company as determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, (with exceptions specified in the Purchase Agreement), or (ii) if the shares are being acquired or held with a purpose or effect of changing or influencing control of the Company, or in connection with or as a participant in any transaction having that purpose or effect, as determined in the sole discretion of the board of directors of the Company. There is no required sinking fund for the Notes. The Notes have not been registered for resale, and the holder(s) do not have registration rights. The Notes restrict the ability of the Company to incur any indebtedness for borrowed money, unless such indebtedness by its terms is expressly subordinated to the Notes in right of payment and to the security interest of the Note holder(s) in respect to the priority and enforcement of any security interest in property of the Company securing such new debt; provided that the Note holder(s) security interest and cash payment rights under the Notes shall be subordinate to a maximum of $5,000,000 of indebtedness for a secured accounts receivable line of credit facility provided to the Company by a bank or institutional lender; and, provided further, that in no event may the amount of indebtedness to which the security interest of the Note holder(s) is subordinated exceed the outstanding balance of accounts receivable less than 90 days old for which the Company has not recorded an allowance for doubtful accounts pledged under such credit facility. The Notes define an event of default generally as any failure by the Company to pay an amount owed under the Notes when due (subject to cure periods), a default with respect to other indebtedness of the Company resulting in acceleration of such indebtedness, the commencement of bankruptcy or insolvency proceedings, or the cessation of business. If an event of default occurs under the Notes, the holder(s) of a majority-in-interest of the outstanding principal amount of the Notes may declare the outstanding principal amount thereof to be immediately due and payable and pursue all available remedies, including taking possession of the assets of the Company and selling them to pay the amount of debt then due, plus expenses, in accordance with applicable laws and procedures. The Company incurred debt issuance costs of approximately $0.1 million, which were recorded as a debt discount and amortized to interest expense over the original repayment period using the effective interest rate method. The interest expense related to the debt discount during the three and nine months ended September 30, 2019 was approximately zero and during the three and nine months ended September 30, 2018 was approximately $6,000 and $30,000, respectively. In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from a public offering of securities effected in October 2018 to repay a portion of the Notes. As of September 30, 2019, the outstanding convertible notes payable of $2.9 million were due in August 2023. In February 2019 and August 2019, semi-annual interest payments of approximately $78,000 and $109,000, respectively, were paid in-kind with the issuance of an additional note (the Interest Note) to the Purchasers. The Interest Notes have terms identical to the Notes. As of September 30, 2019, the Notes and Interest Note could be converted into a maximum of 244,884 shares of common stock at $11.434 per share, excluding the effects of future payments of interest in-kind and a beneficial ownership ceiling of 9.9%.

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Note 9. Leases Effective January 1, 2019, the Company adopted ASU No. 2016-02, as amended, using the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the “effective date method”). Under the effective date method, comparative periods are presented under previous GAAP, Accounting Standards Codification 840, and do not include any retrospective adjustments to reflect the adoption of ASU No. 2016-02. As an accounting policy, the Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components. The Company also has elected the package of transition provisions available for existing contracts, which allowed the Company to carryforward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. The adoption did not result in a cumulative-effect adjustment to the opening balance of accumulated deficit. As a result of the adoption, the Company recorded an operating lease right-to-use asset of $0.4 million and corresponding short-term and long-term liabilities of $0.2 million and $0.2 million, respectively, as of January 1, 2019. The adoption of ASU No. 2016-02 did not have a material impact on the Company’s condensed consolidated statement of operations and comprehensive income or cash flows as of the adoption date. The Company identified only one lease to be accounted for under ASU No. 2016-02, and this was the lease for its corporate facility, which expires in October 2020. The right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. The discount rate used to measure the lease asset and liability represents the interest rate on the Notes (8%). Lease expense is recognized on a straight-line basis over the lease term, and operating lease expense was $0.2 million for the nine months ended September 30, 2019. The Company has an option to extend the lease for an additional 20.5 month period, but, as the renewal is not reasonably certain, it has not included this renewal option in its accounting for the lease. Our future minimum payments under our facility operating lease as of September 30, 2019 are listed in the table below (in thousands). Operating Year ended December 31, lease 2019 $ 55 2020 187 Total future lease payments 242 Less: imputed interest (26 ) Present value of lease liabilities $ 216 Supplemental cash flow information related to the operating lease was as follows (in thousands): Nine months ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 163

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.
Reverse Stock Split	Reverse Stock Split On August 27, 2019, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by the Company’s stockholders and board of directors, respectively. As a result of the reverse stock split, which was effective August 28, 2019, every 20 shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split; stockholders who would otherwise hold a fractional share of the Company’s common stock received cash in an amount equal to the product obtained by multiplying (i) the closing sale price of the common stock on the effective date of the reverse stock split as reported on The Nasdaq Stock Market, by (ii) the number of shares of the common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest. All stock options and restricted stock units outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by 20 and, as applicable, multiplying the exercise price by 20, as a result of the reverse stock split.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Cash Equivalents and Investments	Cash Equivalents and Investments The Company invests its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method.
Fair Value Measurements	Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. There was no allowance for doubtful accounts receivable at either September 30, 2019 or December 31, 2018.
Inventories	Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded no material inventory write-downs during the three and nine months ended September 30, 2019 and $0.1 million of inventory write-downs during the three and nine months ended September 30, 2018.
Revenue Recognition	Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company's contracts have a single performance obligation to transfer products. Accordingly, the recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company its and generally under agreements with payment terms typically less than 60 days. The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. During the nine months ended September 30, 2019, the Company recognized revenue of $0.3 million that had been included in deferred revenue at December 31, 2018. See Note 5 for disaggregation of revenue by geography.
Cost of Net Revenue	Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products.
Goodwill	Goodwill The Company determines the amount of potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired. If the carrying value of the reporting unit’s goodwill exceeds its fair value, then the Company must record an impairment charge equal to the difference. The Company performed its annual test for goodwill impairment as of September 1, 2019, and, due to a decrease in the price per share of its common stock, the test results indicated the goodwill carrying value was greater than its implied fair value. Further, the Company concluded a triggering event had occurred due to the sustained decrease in the price per share of its common stock and related reduced market capitalization as of September 30, 2019 and performed an additional test for impairment of its goodwill asset resulting in further indication that the goodwill carrying value was still greater than its implied fair value. As a result of both of these tests, the Company recorded non-cash impairment charges totaling $0.4 million. As a result of these charges, the Company’s goodwill balance was reduced to zero at September 30, 2019.
Warrants	Warrants As of September 30, 2019 and December 31, 2018, the Company had the following outstanding warrants to purchase common stock: Warrant type Number of shares Exercise Price Expiration date Pre-funded common stock 115,538 $ 0.02 None Common stock 33,125 $ 47.00 January 2023 Common stock 1,845,540 $ 6.00 October 2023
Per Share Amounts	Per Share Amounts Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with the outstanding convertible notes. The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except per share amounts): Three months ended Nine months ended September 30, September 30, 2019 2018 2019 2018 Numerator: Net loss $ (1,801 ) $ (2,812 ) $ (1,894 ) $ (2,149 ) Denominator: Weighted-average common shares outstanding 2,171 412 2,161 409 Total shares: basic and diluted 2,171 412 2,161 409 Net loss per share: Basic and diluted $ (0.83 ) $ (6.83 ) $ (0.88 ) $ (5.25 ) The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): September 30, 2019 2018 Options to purchase common stock 81 17 Unvested restricted common stock units 91 19 Convertible debt 245 118 Warrants 1,994 33 Total 2,411 187
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) Codification Improvements to Topic 842 Leases (Topic 842): Targeted Improvements Leases (Topic 842): Codification Improvements, In 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718), Improvements to Employee Share-based Payment Accounting

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of outstanding warrants to purchase of common stock	As of September 30, 2019 and December 31, 2018, the Company had the following outstanding warrants to purchase common stock: Warrant type Number of shares Exercise Price Expiration date Pre-funded common stock 115,538 $ 0.02 None Common stock 33,125 $ 47.00 January 2023 Common stock 1,845,540 $ 6.00 October 2023
Summary of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except per share amounts): Three months ended Nine months ended September 30, September 30, 2019 2018 2019 2018 Numerator: Net loss $ (1,801 ) $ (2,812 ) $ (1,894 ) $ (2,149 ) Denominator: Weighted-average common shares outstanding 2,171 412 2,161 409 Total shares: basic and diluted 2,171 412 2,161 409 Net loss per share: Basic and diluted $ (0.83 ) $ (6.83 ) $ (0.88 ) $ (5.25 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): September 30, 2019 2018 Options to purchase common stock 81 17 Unvested restricted common stock units 91 19 Convertible debt 245 118 Warrants 1,994 33 Total 2,411 187

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of estimated fair values of financial instruments outstanding	The estimated fair values of financial instruments outstanding were (in thousands): September 30, 2019 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,170 $ — $ — $ 6,170 Short-term investments 649 1 — 650 $ 6,819 $ 1 $ — $ 6,820 December 31, 2018 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 7,104 $ — $ — $ 7,104
Schedule of fair value hierarchy for financial assets (cash equivalents and investments)	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): September 30, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 4,202 $ 4,202 $ — $ — Corporate notes and commercial paper $ 650 $ — $ 650 $ — December 31, 2018 Fair Value Level 1 Level 2 Level 3 Money market funds $ 632 $ 632 $ — $ —

Balance Sheet Detail (Tables)

Balance Sheet Detail (Tables)	9 Months Ended
	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of inventory	September 30, December 31, 2019 2018 (in thousands) Inventories: Work-in-process $ 755 $ 548 Finished goods 460 600 $ 1,215 $ 1,148

Business Segments, Concentrat_2

Business Segments, Concentration of Credit Risk and Significant Customers (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of revenue from shipment of product and licensing of its technologies to customers by geographical location	The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 930 $ 3,652 $ 6,004 $ 10,393 Japan 179 364 1,431 2,206 Taiwan 97 155 225 311 Rest of world — 172 132 239 Total net revenue $ 1,206 $ 4,343 $ 7,792 $ 13,149
Schedule of customers who accounted for at least 10% of total net revenue	Customers who accounted for at least 10% of total net revenue were: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Customer A 33% 37% 27% 34% Customer B 19% 29% 20% 15% Customer C 19% *% *% *% Customer D 15% *% 18% 17% Customer E *% *% 17% 18% * Represents less than 10%

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of assumptions used in estimation of fair value of the share-based payment awards on the grant date	Nine Months Ended September 30, 2019 2018 Risk-free interest rate 2.5 % 2.2 % Volatility 128.4 % 109.5 % Expected life (years) 3.0 - 5.0 4.0 Dividend yield — % — %
Summary of option and RSU activity under Amended and Restated 2000 Stock Option and Equity Incentive Plan and Amended and Restated 2010 Equity Incentive Plan	A summary of option and RSU activity under the Company’s Amended and Restated 2010 Equity Incentive Plan (the 2010 Plan) is presented below (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2019 200 17 $ 83.80 Additional shares authorized under the Plan 2 — — RSUs granted (101 ) — — RSUs cancelled and returned to the Plan 1 — — Options granted (65 ) 65 $ 4.00 Balance as of March 31, 2019 37 82 $ 20.40 RSUs granted (6 ) — — Options cancelled and returned to the Plan 1 (1 ) $ 144.00 Balance as of June 30, 2019 32 81 $ 20.00 Plan termination (32 ) — $ — Balance as of September 30, 2019 - 81 $ 20.00
Summary of RSU activity under the Plan	A summary of RSU activity under the Plan is presented below (in thousands, except for fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2019 14 $ 24.60 Granted 101 $ 4.00 Vested (8 ) $ 29.60 Cancelled (1 ) $ 25.20 Non-vested shares as of March 31, 2019 106 $ 4.60 Granted 6 $ 4.60 Vested (5 ) $ 16.20 Non-vested shares as of June 30, 2019 107 $ 4.00 Vested (16 ) $ 4.00 Non-vested shares as of September 30, 2019 91 $ 4.00
Summary of significant ranges of outstanding and exercisable options	The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2019 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $3.72 - $14.99 64 9.35 $ 3.96 11 $ 4.00 $ — $15.00 - $25.59 8 4.05 $ 15.00 5 $ 15.00 $ — $25.60 - $143.99 3 4.83 $ 41.88 2 $ 46.93 $ — $144.00 - $409.99 5 6.90 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 5.44 $ 430.64 1 $ 430.64 $ — $3.72 - $924.00 81 8.46 $ 20.36 24 $ 56.81 $ —

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Schedule of Future Minimum Payments under Facility Operating Lease	Our future minimum payments under our facility operating lease as of September 30, 2019 are listed in the table below (in thousands). Operating Year ended December 31, lease 2019 $ 55 2020 187 Total future lease payments 242 Less: imputed interest (26 ) Present value of lease liabilities $ 216
Schedule of Supplemental Cash Flow Information Related to Operating lease	Supplemental cash flow information related to the operating lease was as follows (in thousands): Nine months ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 163

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies - Additional Information (Details)	Aug. 27, 2019	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Accounting Policies [Abstract]
Reverse stock split	20
Maximum specific allowance as percentage of invoice value for problematic customer balances		100.00%		100.00%
Allowance for doubtful accounts receivable		$ 0		$ 0			$ 0
Inventory reserves		0	$ 100,000	$ 0	$ 100,000
Payment terms				The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days.
Deferred revenue, revenue recognized				$ 300,000
Impairment of goodwill		420,000	$ 3,159,000	420,000	$ 3,159,000
Goodwill balance		0		0			$ 420,000
Right-of-use lease asset		203,000		203,000		$ 400,000
Lease liabilities		$ 216,000		$ 216,000		$ 400,000

The Company and Summary of Si_5

The Company and Summary of Significant Accounting Policies - Summary of Outstanding Warrants to Purchase Common Stock (Detail) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Pre Funded Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Number of shares	115,538	115,538
Exercise Price	$ 0.02	$ 0.02
Common Stock Warrants One
Class Of Warrant Or Right [Line Items]
Number of shares	33,125	33,125
Exercise Price	$ 47	$ 47
Expiration date	Jan. 30, 2023	Jan. 30, 2023
Common Stock Warrants Two
Class Of Warrant Or Right [Line Items]
Number of shares	1,845,540	1,845,540
Exercise Price	$ 6	$ 6
Expiration date	Oct. 30, 2023	Oct. 30, 2023

The Company and Summary of Si_6

The Company and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Numerator:
Net income (loss)	$ (1,801)	$ (103)	$ 10	$ (2,812)	$ 315	$ 348	$ (1,894)	$ (2,149)
Weighted-average common shares outstanding	2,171			412			2,161	409
Basic and diluted	2,171			412			2,161	409
Net loss per share:
Basic and diluted	$ (0.83)			$ (6.83)			$ (0.88)	$ (5.25)

The Company and Summary of Si_7

The Company and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,411	187
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	81	17
RSU's
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	91	19
Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	245	118
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,994	33

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Estimated Fair Values of Financial Instruments Outstanding (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Cost	$ 6,819
Unrealized Gains	1
Unrealized Losses	0
Fair Value	6,820
Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Cost	6,170	$ 7,104
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	6,170	$ 7,104
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Cost	649
Unrealized Gains	1
Unrealized Losses	0
Fair Value	$ 650

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy for Financial Assets (Cash Equivalents and Investments) (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 4,202	$ 632
Corporate notes and commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	650
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	4,202	$ 632
Level 2 | Corporate notes and commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 650

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Detail)	Sep. 30, 2019USD ($)
Fair Value Disclosures [Abstract]
Transfer of assets between Level 1 to Level 2	$ 0
Transfer of assets between Level 2 to Level 1	0
Transfer of liabilities between Level 1 to Level 2	0
Transfer of liabilities between Level 2 to Level 1	$ 0

Balance Sheet Detail - Schedule

Balance Sheet Detail - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Work-in-process	$ 755	$ 548
Finished goods	460	600
Total	$ 1,215	$ 1,148

Business Segments, Concentrat_3

Business Segments, Concentration of Credit Risk and Significant Customers - Additional Information (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2019SegmentCustomer	Dec. 31, 2018Customer
Business Segments
Number of business segments | Segment	1
Number of measurements of profitability	1
Accounts receivable | Major customers | Credit concentration
Business Segments
Percentage of concentration risk	76.00%	63.00%
Number of customers | Customer	3	3

Business Segments, Concentrat_4

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Segments
Total net revenue	$ 1,206	$ 4,343	$ 7,792	$ 13,149
North America [Member]
Business Segments
Total net revenue	930	3,652	6,004	10,393
Japan [Member]
Business Segments
Total net revenue	179	364	1,431	2,206
Taiwan [Member]
Business Segments
Total net revenue	$ 97	155	225	311
Rest of world [Member]
Business Segments
Total net revenue		$ 172	$ 132	$ 239

Business Segments, Concentrat_5

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue (Detail) - Net Revenues - Customer Concentration	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Customer A
Significant Customers
Percentage of concentration risk	33.00%	37.00%	27.00%	34.00%
Customer B
Significant Customers
Percentage of concentration risk	19.00%	29.00%	20.00%	15.00%
Customer C
Significant Customers
Percentage of concentration risk	19.00%
Customer D
Significant Customers
Percentage of concentration risk	15.00%		18.00%	17.00%
Customer E
Significant Customers
Percentage of concentration risk			17.00%	18.00%

Income Tax Provision - Addition

Income Tax Provision - Additional Information (Detail)	Sep. 30, 2019USD ($)
Income Tax Disclosure [Abstract]
Unrecognized tax benefits recorded as liability	$ 0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted (in shares)	0			0
Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted (in shares)		32,000	37,000				200,000
Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance	182,500				182,500
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unamortized compensation cost, net of expected forfeitures	$ 200,000				$ 200,000
Weighted average expected period over which the expense is to be recognized					2 years 2 months 12 days
Tax benefits associated with exercise of stock options	$ 0			$ 0	$ 0	$ 0
Dividend yield (as a percent)					0.00%	0.00%
Stock options exercised					0	0
Options | Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted (in shares)					0
Options | Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum percentage of voting rights required for applicability of a specific expiration term	10.00%				10.00%
Maximum expiration term of options granted					5 years
Term of plan					10 years
Options granted (in shares)	0				0
Options | Maximum | Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options					4 years
Options | Minimum | Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options					3 years
RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average expected period over which the expense is to be recognized					2 years 3 months 18 days
Unamortized compensation cost, net of expected forfeitures	$ 300,000				$ 300,000
RSU's | Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of the restricted stock units outstanding	$ 200,000				$ 200,000
Granted (in shares)		6,000	101,000
RSU's | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense, recognition period					5 years
RSU's | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense, recognition period					3 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of the Share-based Payment Awards on the Grant Date (Detail) - Options	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	2.50%	2.20%
Volatility	128.40%	109.50%
Expected life (years)		4 years
Dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	5 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Option and RSU Activity under Equity Incentive Plan and Amended and Restated 2010 Equity Incentive Plan (Detail) - Equity Incentive Plan 2010 - $ / shares	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2019
Shares Available for Grant
Balance at the beginning of the year (in shares)	32,000	37,000	200,000	200,000
Options granted (in shares)			(65,000)
Options cancelled and returned to Plan (in shares)		1,000
Plan termination (in shares)	(32,000)
Balance at the end of the period (in shares)		32,000	37,000
Number of shares
Balance at the beginning of the year (in shares)	81,000	82,000	17,000	17,000
Options granted (in shares)			65,000
Balance at the end of the period (in shares)	81,000	81,000	82,000	81,000
Options cancelled and returned to Plan (in shares)		(1,000)
Weighted Average Exercise Prices
Weighted-average exercise price (in dollars per share)	$ 20	$ 20.40	$ 83.80	$ 83.80
Options granted (in dollars per share)			4
Options cancelled and returned to Plan (in dollars per share)		144
Weighted-average exercise price (in dollars per share)	$ 20	$ 20	$ 20.40	$ 20
Options
Shares Available for Grant
Additional shares authorized under the Plan			2,000
RSUs granted (in shares)				0
RSU's
Shares Available for Grant
RSUs granted (in shares)		(6,000)	(101,000)
RSUs cancelled and returned to Plan (in shares)			1,000
Number of shares
RSUs cancelled and returned to Plan (in shares)			1,000
Weighted Average Exercise Prices
RSUs granted (in dollars per share)		$ 4.60	$ 4
RSUs cancelled and returned to Plan (in dollars per shares)			$ 25.20

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity under the Plan (Detail) - Equity Incentive Plan 2010 - RSU's - $ / shares	3 Months Ended			9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2019
Number of Shares
Non-vested shares at the beginning of the year	107,000	106,000	14,000	14,000
Granted (in shares)		6,000	101,000
Vested (in shares)	(16,000)	(5,000)	(8,000)
Cancelled (in shares)			(1,000)
Non-vested shares at the end of the period	91,000	107,000	106,000	91,000
Weighted Average Grant-Date Fair Value
Weighted average grant date fair value	$ 4	$ 4.60	$ 24.60	$ 24.60
Granted (in shares)		4.60	4
Vested (in shares)	4	16.20	29.60
Cancelled (in shares)			25.20
Weighted average grant date fair value	$ 4	$ 4	$ 4.60	$ 4

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Significant Ranges of Outstanding and Exercisable Options (Detail) - Options shares in Thousands	9 Months Ended
	Sep. 30, 2019$ / sharesshares
$3.72 - $14.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 3.72
Upper range limit (in dollars per share)	$ 14.99
Number Outstanding (in shares) | shares	64
Weighted Average Remaining Contractual Life	9 years 4 months 6 days
Weighted Average Exercise Price (in dollars per share)	$ 3.96
Number Exercisable (in shares) | shares | shares	11
Weighted Average Exercise Price (in dollars per share)	$ 4
$15.00 - $25.59
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	15
Upper range limit (in dollars per share)	$ 25.59
Number Outstanding (in shares) | shares	8
Weighted Average Remaining Contractual Life	4 years 18 days
Weighted Average Exercise Price (in dollars per share)	$ 15
Number Exercisable (in shares) | shares | shares	5
Weighted Average Exercise Price (in dollars per share)	$ 15
$25.60 - $143.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	25.60
Upper range limit (in dollars per share)	$ 143.99
Number Outstanding (in shares) | shares	3
Weighted Average Remaining Contractual Life	4 years 9 months 29 days
Weighted Average Exercise Price (in dollars per share)	$ 41.88
Number Exercisable (in shares) | shares | shares	2
Weighted Average Exercise Price (in dollars per share)	$ 46.93
$144.00 - $409.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	144
Upper range limit (in dollars per share)	$ 409.99
Number Outstanding (in shares) | shares	5
Weighted Average Remaining Contractual Life	6 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 144
Number Exercisable (in shares) | shares | shares	5
Weighted Average Exercise Price (in dollars per share)	$ 144
$410.00 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	410
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares) | shares	1
Weighted Average Remaining Contractual Life	5 years 5 months 8 days
Weighted Average Exercise Price (in dollars per share)	$ 430.64
Number Exercisable (in shares) | shares | shares	1
Weighted Average Exercise Price (in dollars per share)	$ 430.64
$3.72 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	3.72
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares) | shares	81
Weighted Average Remaining Contractual Life	8 years 5 months 15 days
Weighted Average Exercise Price (in dollars per share)	$ 20.36
Number Exercisable (in shares) | shares | shares	24
Weighted Average Exercise Price (in dollars per share)	$ 56.81

Convertible Notes - Additional

Convertible Notes - Additional Information (Details) - USD ($)	Feb. 18, 2018	Feb. 17, 2018	Aug. 31, 2019	Feb. 28, 2019	Oct. 31, 2018	Mar. 31, 2016	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Debt Instrument [Line Items]
Stated interest rate							8.00%		8.00%
Interest expense							$ 54,000	$ 104,000	$ 164,000	$ 531,000
Senior Secured Convertible Notes due August 15 2018
Debt Instrument [Line Items]
Stated interest rate					8.00%	10.00%
Principal amount						$ 8,000,000
Redemption purchase price	100.00%	120.00%
Minimum ownership percentage triggering event for redemption of notes						40.00%
Maximum amount of indebtedness subordinated by security interest and cash payment rights under debt instruments						$ 5,000,000
Payment on principle amount of note					$ 7,400,000
Senior Secured Convertible Notes due August 15 2018 | Contractual obligations and other termination costs
Debt Instrument [Line Items]
Debt issuance costs						$ 100,000
Interest expense							$ 0	$ 6,000	$ 0	$ 30,000
Senior Secured Convertible Notes due August 15 2018 | Maximum
Debt Instrument [Line Items]
Period for outstanding balance of accounts receivable has not recorded an allowance for doubtful accounts						90 days
Senior Secured Convertible Notes due August 15 2018 | Minimum
Debt Instrument [Line Items]
Percentage of beneficial ownership if effective upon conversion date of debt instrument						19.90%
Interest Note
Debt Instrument [Line Items]
Conversion price							$ 11.434		$ 11.434
Semi-annual interest payments			$ 109,000	$ 78,000
Number of shares issuable if notes converted to shares of common stock									244,884
Beneficial ownership ceiling							9.90%		9.90%
Senior Secured Convertible Notes due August 15, 2023
Debt Instrument [Line Items]
Conversion price					$ 11.434	$ 170
Outstanding Notes payable							$ 2,900,000		$ 2,900,000

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Jan. 01, 2019
Leases [Abstract]
Right-of-use lease asset	$ 203	$ 400
Short-term lease liability	$ 197	200
Long-term lease liability		$ 200
Interest rate	8.00%
Operating leases expense	$ 200
Operating leases expiration period	2020-10
Option to extend additional lease term	20 months 15 days
Operating lease, option to extend	option to extend the lease for an additional 20.5 month period

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments under Facility Operating Lease (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019
Leases, Operating [Abstract]
2019	$ 55
2020	187
Total future lease payments	242
Less: imputed interest	(26)
Present value of lease liabilities	$ 216	$ 400

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating lease (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for lease	$ 163